{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["trastuzumab emtansine","osimertinib"]],"indication":"EGFR mutation-positive NSCLC with HER2 bypass track resistance","name":"TRAEMOS","nct_id":"NCT03784599","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=traemos-nct03784599. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRAEMOS","arms":[{"description":"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks\n\nOsimertinib 80 mg once daily, orally, continuous\n\nTreatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs.","label":"Trastuzumab-emtansine and osimertinib","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","Roche Pharma AG"],"completion_date":{"date":"2021-05-17","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab emtansine","otherNames":[],"type":"DRUG"},{"name":"Osimertinib","otherNames":[],"type":"DRUG"}],"last_update":"2022-11-10","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-05-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Safety (intensity and incidence of adverse events)","timeFrame":"Up to 30 days after last study drug intake"},{"measure":"Objective response rate according to RECIST v1.1 after 3 months of treatment","timeFrame":"From date of registration until 3 months."}],"references":[],"start_date":{"date":"2018-12-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC","url":"https://clinicaltrials.gov/study/NCT03784599"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/traemos-nct03784599"}